How it works

Bunavail is a buccal film that contains both buprenorphine and naloxone.

Buprenorphine is an opioid (narcotic) with a distinct and complicated mechanism of action that includes partial binding to mu-opioid receptors and a complete binding to kappa-opioid receptors. Opioid receptors have three main effects: they reduce breathing (respiratory depression), they produce euphoria (intense happiness or excitement), and they reduce pain.

Because of the way buprenorphine binds, it can satisfy opioid cravings without causing euphoria or significant respiratory depression. Furthermore, while it is bound to opioid receptors, it prevents other opioids (such as heroin or oxycodone) from binding. It also stays on the receptors for a longer period of time - about three days - making it an excellent choice for use in opioid addiction treatment programs.

To discourage misuse, this combination tablet contains Naloxone. If drug users attempt to convert the film into an injectable form, they will experience opioid withdrawal because naloxone is a very strong mu opioid receptor blocker. Sublingual absorption of naloxone is poor (under the tongue).

Bunavail is a medication in the class known as combination opioid/opioid antagonists.

In the United States, the Bunavail brand name has been discontinued.